FOSCLERA gastroresistentne kõvakapsel Eesti - eesti - Ravimiamet

fosclera gastroresistentne kõvakapsel

norameda uab - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 56tk

DIMETHYL FUMARATE TEVAPHARM gastroresistentne kõvakapsel Eesti - eesti - Ravimiamet

dimethyl fumarate tevapharm gastroresistentne kõvakapsel

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 100tk; 120mg 14tk

DIMETHYL FUMARATE TEVAPHARM gastroresistentne kõvakapsel Eesti - eesti - Ravimiamet

dimethyl fumarate tevapharm gastroresistentne kõvakapsel

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 168tk

SERYNOX meditsiiniline surugaas Eesti - eesti - Ravimiamet

serynox meditsiiniline surugaas

aktsiaselts elme messer gaas - dilämmastikoksiid+hapnik - meditsiiniline surugaas - 50%+50% 2l 1tk; 50%+50% 15l 1tk; 50%+50% 10l 1tk; 50%+50% 5l 1tk

Hemangiol Euroopa Liit - eesti - EMA (European Medicines Agency)

hemangiol

pierre fabre medicament - propranoloolvesinikkloriid - hemangioom - beetablokaatorid - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

DENTOCAINE 40MG/0,005 MG/ML süstelahus Eesti - eesti - Ravimiamet

dentocaine 40mg/0,005 mg/ml süstelahus

inibsa dental s.l. - artikaiin+epinefriin (adrenaliin) - süstelahus - 40mg+0,005mg 1ml 1.8ml 50tk

DENTOCAINE 40MG/0,01 MG/ML süstelahus Eesti - eesti - Ravimiamet

dentocaine 40mg/0,01 mg/ml süstelahus

inibsa dental s.l. - artikaiin+epinefriin (adrenaliin) - süstelahus - 40mg+0,01mg 1ml 1.8ml 100tk; 40mg+0,01mg 1ml 1.8ml 50tk

Libmeldy Euroopa Liit - eesti - EMA (European Medicines Agency)

libmeldy

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muud närvisüsteemi ravimid - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

TOT'HEMA suukaudne lahus Eesti - eesti - Ravimiamet

tot'hema suukaudne lahus

laboratoire innotech international - raud(ii)glükonaat+mangaanglükonaat+vaskglükonaat - suukaudne lahus - 5mg+0,133mg+0,07mg 1ml 10ml 20tk